InMed Pharmaceuticals Inc
INM2.370USD
-0.020-0.84%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
2.86MValor de mercado
PerdaP/L TTM
Mais detalhes de InMed Pharmaceuticals Inc Empresa
InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Informações da empresa
Código da empresaINM
Nome da EmpresaInMed Pharmaceuticals Inc
Data de listagemJun 21, 2001
CEOMr. Eric A. Adams
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 21
Endereço1445-885 West Georgia St.
CidadeVANCOUVER
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísCanada
Código postalV6C 3E8
Telefone16046697207
Sitehttps://www.inmedpharma.com/
Código da empresaINM
Data de listagemJun 21, 2001
CEOMr. Eric A. Adams
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
-18.19%
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
-99.90%
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
-99.96%
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
-18.19%
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
-99.90%
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
-99.96%
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 11 de jul
Atualizado em: sex, 11 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Yorkville Advisors Global, LP.
6.66%
Sabby Management, LLC
2.99%
UBS Financial Services, Inc.
0.51%
Adams (Eric Ashley)
0.18%
Hull (Andrew Harold)
0.16%
Other
89.50%
Investidores
Investidores
Proporção
Yorkville Advisors Global, LP.
6.66%
Sabby Management, LLC
2.99%
UBS Financial Services, Inc.
0.51%
Adams (Eric Ashley)
0.18%
Hull (Andrew Harold)
0.16%
Other
89.50%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
9.65%
Individual Investor
0.98%
Investment Advisor
0.51%
Research Firm
0.03%
Other
88.84%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
37
127.03K
10.52%
+19.01K
2025Q1
34
127.03K
10.75%
+32.44K
2024Q4
33
169.52K
14.04%
+76.54K
2024Q3
35
65.17K
63.92%
+11.73K
2024Q2
34
30.10K
7.60%
-6.51K
2024Q1
33
42.40K
13.49%
-1.13K
2023Q4
31
40.41K
15.37%
-91.29K
2023Q3
32
1.59K
1.33%
-12.58K
2023Q2
37
1.04K
0.99%
-13.60K
2023Q1
44
5.33K
3.61%
-4.80K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Yorkville Advisors Global, LP.
80.37K
6.66%
+80.37K
--
Dec 13, 2024
Sabby Management, LLC
36.13K
2.99%
+20.77K
+135.22%
Dec 31, 2024
UBS Financial Services, Inc.
6.11K
0.51%
-4.30K
-41.33%
Mar 31, 2025
Adams (Eric Ashley)
7.89K
0.65%
+5.70K
+259.26%
May 11, 2025
Hull (Andrew Harold)
2.34K
0.19%
+425.00
+22.23%
May 11, 2025
SBI Securities Co., Ltd.
300.00
0.02%
+300.00
--
Mar 31, 2025
Banque Cantonale Vaudoise
6.00
0%
--
--
Mar 31, 2025
Hsu (Eric Chih-Hsien)
1.95K
0.16%
+1.95K
+97300.00%
May 11, 2025
AllSquare Wealth Management LLC
1.00
0%
--
--
Mar 31, 2025
Desjardins Securities Inc.
1.00
0%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
AdvisorShares Pure Cannabis ETF
0%
AdvisorShares Pure Cannabis ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Aug 26, 2022
Merger
25<1
Aug 26, 2022
Merger
25<1
Data
Tipo
Proporção
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Aug 26, 2022
Merger
25<1
Aug 26, 2022
Merger
25<1
Aug 26, 2022
Merger
25<1
Aug 26, 2022
Merger
25<1
